Expansion of NK cell-based immunotherapy into pet healthcare… advancing a data-driven precision healthcare model
NKCL Bio Group Co., Ltd. (CEO: Donghwa Shin), a biotechnology company specializing in immune cell-based technologies, has officially entered the companion animal immune healthcare market.
The company announced that it recently signed a memorandum of understanding (MOU) with Dangnyangi & People Co., Ltd., a pet life-care platform company, to jointly develop immune-based healthcare technologies and products for companion animals. Through this partnership, NKCL aims to expand the application of its NK cell-based immunotherapy into the pet market.
Entry into ‘Pet Bio’ leveraging NK cell cultivation and activation technologies
NKCL Bio Group has been advancing the development of anti-cancer and immunotherapeutic solutions based on its proprietary NK cell mass cultivation and activation control technologies.
Its core competencies include high-efficiency NK cell expansion, personalized cell activation modulation, cytokine secretion control, and automated cell culture systems.
Notably, its capability to produce tens of billions of NK cells within two weeks, along with GMP-level manufacturing infrastructure, is recognized as a scalable foundation for broader applications.
Building on these capabilities, NKCL plans to extend into bio-healthcare solutions for companion animals, including cancer treatment, immune enhancement, aging management, and chronic disease response.
Integration with AI platform data… realization of precision healthcare
A key element of this collaboration lies in integrating NKCL’s biotechnology with platform-based data.
Dangnyangi & People accumulates diverse pet-related data—such as health status, behavioral patterns, and lifestyle information—through its AI-driven pet healthcare platform.
Both companies intend to leverage this data to develop a precision pet healthcare model encompassing individual immune profiling, customized bio-material application, and preventive healthcare service design.
Preclinical validation supports broader application potential
NKCL has previously demonstrated tumor suppression effects of NK cells across multiple cancer types in preclinical studies.
The company has also validated the potential for regulating immune disorders and inflammatory responses through multi-mechanistic actions, including ADCC and cytokine modulation.
Industry experts anticipate that these technologies could expand into the pet sector, addressing immune deficiencies, inflammatory diseases, age-related conditions, and next-generation anti-cancer therapies.
“Transferring human bio-technology to the pet market”
An NKCL representative stated, “This collaboration marks a significant milestone in extending NK cell-based immunotherapy from human healthcare to companion animal healthcare. By integrating with AI data platforms, we aim to deliver highly precise and personalized immune healthcare services.”
The company further noted its mid- to long-term goal of advancing technological capabilities and commercialization to enter the global pet bio market.
Parallel advancement of clinical and regulatory strategies
NKCL plans to sequentially pursue non-clinical and clinical validation for companion animals, establish regulatory approval strategies by product category, and commercialize bio-based materials.
Through this collaboration, the company aims to expand the application scope of cell therapy technologies and lead a paradigm shift toward bio-centered innovation within the pet healthcare industry.
Cancer remains the leading cause of death in companion animals.
The industry expects this partnership to stimulate demand for high-value anti-cancer treatments within Korea’s 15 million companion animal population market.
